Ansioluettelo

Biotech professional with 20 years of operational pharma / biotech experience. Track record of more than 50 drug development programs, incl. small molecules, recombinant proteins, peptides and biologicals from discovery into late clinical development in multiple therapeutic areas. Big pharma experience from AstraZeneca, toxicology project lead and portfolio management within Respiratory / Inflammation (Lund, Sweden) and CNS / Pain research areas (Montreal, Canada). COO of the clinical-stage oncology biotech Cend Therapeutics Inc. (San Diego, CA), with the lead peptide product CEND-1 now ready for the pivotal Phase 2b/3 trials (the only employee of the company from the academic spin-off stage until 2020/Phase 2a).

Veterinary Medicine and PhD degrees from University of Helsinki, postdoctoral training at New York University Medical Center (New York, NY) and Max Planck Institute (Berlin, Germany). Adjunct Professor of Toxicology at University of Helsinki since 2004. An author of >40 peer-reviewed scientific publications, patents, book chapters. Toxicology board certification toxicology from the US (DABT) and EU (ERT).